Fields, Bernard N., ed. Fields' Virology 4th edition. Philadelphia: Lippincott-Raven Publishers, 1996.

Ribavirin. (2004). Medline Plus Drug Information. Retrieved Nov. 27, 2005, from

Attenuation of bunyavirus replication by rearrangement of viral coding and noncoding sequences. J Virol. 2005 Jun; 79(11):6940-6. Lowen AC, Boyd A, Fazakerley JK, Elliott RM. Available here.

Production of monoclonal antibodies against Rift Valley fever virus Application for rapid diagnosis tests (virus detection and ELISA) in human sera. J Virol Methods. 2005 Aug 12; , Zaki A, Coudrier D, Yousef AI, Fakeeh M, Bouloy M, Billecocq A.Available here.

Bi-annual surge of Crimean-Congo haemorrhagic fever (CCHF): a five-year experience. Int J Infect Dis. 2005 Jan;9(1):37-42. , Sheikh AS, Sheikh AA, Sheikh NS, Rafi-U-Shan, Asif M, Afridi F, Malik MT.Available here.

California serogroup Gc (G1) glycoprotein is the principal determinant of pH-dependent cell fusion and entry. Virology. 2005 Jul 20;338(1):121-32. Plassmeyer ML, Soldan SS, Stachelek KM, Martin-Garcia J, Gonzalez-Scarano F. Available here.

The Bunyamwera virus mRNA transcription signal resides within both the 3' and the 5' terminal regions and allows ambisense transcription from a model RNA segment. J Virol. 2005 Oct;79(19):12602-7. Barr JN, Rodgers JW, Wertz GW. Available here.

Complementarity, sequence and structural elements within the 3' and 5' non-coding regions of the Bunyamwera orthobunyavirus S segment determine promoter strength. J Gen Virol. 2004 Nov;85(Pt 11):3269-78. Kohl A, Dunn EF, Lowen AC, Elliott RM. Available here.

Back to Bunyavirus!